PUT/NOVO-NORDISK B/550/2/21.06.24 | Real-time BOERSE MUENCHEN 09:56:14 10/06/2024 pm IST | ||
| 0.073 EUR | -17.98% |
|
| Current month | +11.25% | ||
| 1 month | -51.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 0.073 | -17.98% |
| 07/24/07 | 0.089 | +1.14% |
| 06/24/06 | 0.088 | +175.00% |
| 05/24/05 | 0.032 | -57.89% |
| 04/24/04 | 0.076 | -20.00% |
Real-time BOERSE MUENCHEN
Last update June 10, 2024 at 09:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GP7XLZ |
| ISIN | DE000GP7XLZ5 |
| Date issued | 12/07/2023 |
| Strike | 550 kr |
| Maturity | 21/06/2024 (11 Days) |
| Parity | 0.5 : 1 |
| Emission price | 17.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.22 € |
|---|---|
| Lowest since issue | 0.017 € |
| Spread | 3 € |
| Spread % | 99.01% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Warrants
- Warrant
